• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Annual Changes to the Nasdaq-100 Index®

    12/12/25 8:00:00 PM ET
    $ALNY
    $BIIB
    $CDW
    $FER
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALNY alert in real time by email

    NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NDX®), which will become effective prior to market open on Monday, December 22, 2025.

    The following six companies will be added to the Index: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Ferrovial SE (NASDAQ:FER), Insmed Incorporated (NASDAQ:INSM), Monolithic Power Systems, Inc. (NASDAQ:MPWR), Seagate Technology Holdings plc (NASDAQ:STX), Western Digital Corp. (NASDAQ:WDC).

    The Nasdaq-100 Index is a globally recognized index that tracks the performance of 100 of the largest non-financial companies listed on the Nasdaq Stock Market® encompassing a diverse range of industries and sectors. From technology and retail to healthcare, telecommunications, biotechnology, and media, these companies collectively shape the new 21st century economy. The Nasdaq-100® is reconstituted each year in December, timed to coincide with the quadruple witch expiration Friday of the quarter.

    As of December 2025, the Nasdaq-100 Index underpins more than 200 tracking products with over $600 billion in assets under management globally, including the Invesco QQQ Trust (QQQ®), which seeks to deliver investment results that, before expenses, correspond to the performance of the Nasdaq-100 Index. In addition to QQQ, a range of derivatives and structured instruments, such as futures, options, and other products based on the Nasdaq-100 Index and the Invesco QQQ Trust trade on various exchanges.

    As a result of the reconstitution, the following six companies will be removed from the Index: Biogen Inc. (NASDAQ:BIIB), CDW Corporation (NASDAQ:CDW), GlobalFoundries Inc. (NASDAQ:GFS), Lululemon Athletica Inc. (NASDAQ:LULU), ON Semiconductor Corporation (NASDAQ:ON), The Trade Desk, Inc. (NASDAQ:TTD).

    Information

    For information about the six companies to be added to the Nasdaq-100 Index, please visit the following respective company websites:

    • Alnylam Pharmaceuticals, Inc. – https://www.alnylam.com/
    • Ferrovial SE – https://www.ferrovial.com/
    • Insmed Incorporated – https://insmed.com/
    • Monolithic Power Systems, Inc. – https://www.monolithicpower.com/
    • Seagate Technology Holdings plc – https://www.seagate.com/
    • Western Digital Corp. – https://www.westerndigital.com/



    About Nasdaq Global Indexes

    Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend and Income (includes Dividend Achievers), Dorsey Wright, Fixed Income (includes BulletShares®), Global Equity, Green Economy, Nordic, and Commodity indexes. We continuously offer new opportunities for financial product sponsors across a wide spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index, and design solutions to financial organizations worldwide.

    About Nasdaq

    Nasdaq (NASDAQ:NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com

    Nasdaq®, Nasdaq-100 Index®, Nasdaq-100®, NDX®, QQQ®, and Nasdaq Stock Market® are registered trademarks of Nasdaq, Inc. The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither Nasdaq, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies or Nasdaq proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

    Media Relations Contact Investor Relations Contact
    Name: Maximilian Leitenberger

    Email: Maximilian.leitenberger@nasdaq.com



     Name: Index Client Services

    Email: indexservices@nasdaq.com

       

    NDAQF



    Primary Logo

    Get the next $ALNY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALNY
    $BIIB
    $CDW
    $FER

    CompanyDatePrice TargetRatingAnalyst
    The Trade Desk Inc.
    $TTD
    5/28/2026$11.00Sell
    Rothschild & Co Redburn
    Ferrovial SE
    $FER
    5/27/2026$70.00Buy → Neutral
    Citigroup
    CDW Corporation
    $CDW
    5/27/2026$130.00Neutral → Overweight
    Analyst
    Alnylam Pharmaceuticals Inc.
    $ALNY
    5/19/2026$380.00Buy
    Citigroup
    Biogen Inc.
    $BIIB
    5/15/2026Outperform
    Evercore ISI
    ON Semiconductor Corporation
    $ON
    5/13/2026$95.00 → $100.00Neutral
    Cantor Fitzgerald
    Seagate Technology Holdings PLC
    $STX
    5/12/2026$750.00 → $1000.00Outperform
    Evercore ISI
    The Trade Desk Inc.
    $TTD
    5/11/2026$20.00Hold → Reduce
    HSBC Securities
    More analyst ratings

    $ALNY
    $BIIB
    $CDW
    $FER
    SEC Filings

    View All

    Western Digital Corporation filed SEC Form 8-K: Other Events, Unregistered Sales of Equity Securities

    8-K - WESTERN DIGITAL CORP (0000106040) (Filer)

    6/3/26 8:00:06 AM ET
    $WDC
    Electronic Components
    Technology

    The Trade Desk Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Trade Desk, Inc. (0001671933) (Filer)

    6/1/26 4:35:28 PM ET
    $TTD
    Computer Software: Programming Data Processing
    Technology

    SEC Form 144 filed by Alnylam Pharmaceuticals Inc.

    144 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    6/1/26 4:25:14 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    $BIIB
    $CDW
    $FER
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZURZUVAE issued to BIOGEN INC

    Submission status for BIOGEN INC's drug ZURZUVAE (SUPPL-3) with active ingredient ZURANOLONE has changed to 'Approval' on 04/20/2026. Application Category: NDA, Application Number: 217369, Application Classification: Labeling

    4/23/26 6:14:48 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

    9/16/24 6:52:10 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

    9/16/24 6:24:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALNY
    $BIIB
    $CDW
    $FER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

    Designation is supported by an exploratory analysis from the Phase 1b study showing that some children with SMA previously treated with gene therapy who had suboptimal clinical status experienced slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenSalanersen is an investigational antisense oligonucleotide dosed once-yearly with the potential to be a meaningful therapy in the future SMA treatment landscape CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) --   Biogen Inc. (NASDAQ:BIIB) announced today that the U.S. Food and Drug Administration (FDA) has granted salanersen Breakthrough Therapy Designation for the treatment o

    6/4/26 7:30:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., June 4, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 103 new employees. The awards were granted under the Insmed Incorporated 2025 Inducement Plan, which is intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4). The awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.In connection with the commence

    6/4/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

    Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus standard of care, supporting reduced long-term steroid exposureReduced flare rates and immune marker improvements: In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observed, supporting the potential of dapirolizumab pegol to address the complex burden of SLE BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Bi

    6/4/26 1:00:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALNY
    $BIIB
    $CDW
    $FER
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Nelms David W bought $2,005,740 worth of shares (18,000 units at $111.43), increasing direct ownership by 55% to 51,025 units (SEC Form 4)

    4 - CDW Corp (0001402057) (Issuer)

    5/29/26 4:03:28 PM ET
    $CDW
    Retail: Computer Software & Peripheral Equipment
    Technology

    Officer Leahy Christine A bought $499,398 worth of shares (4,830 units at $103.39), increasing direct ownership by 3% to 193,357 units (SEC Form 4)

    4 - CDW Corp (0001402057) (Issuer)

    5/19/26 4:13:00 PM ET
    $CDW
    Retail: Computer Software & Peripheral Equipment
    Technology

    President and CEO Green Jeffrey Terry was granted 398,089 shares and bought $148,101,266 worth of Class A Common Stock (6,000,000 units at $24.68), increasing direct ownership by 154% to 655,917 units (SEC Form 4)

    4 - Trade Desk, Inc. (0001671933) (Issuer)

    3/4/26 8:27:33 PM ET
    $TTD
    Computer Software: Programming Data Processing
    Technology

    $ALNY
    $BIIB
    $CDW
    $FER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, WW Sales & Marketing Sciammas Maurice sold $46,018 worth of shares (30 units at $1,533.95) as part of a pre-agreed trading plan (SEC Form 4)

    4 - MONOLITHIC POWER SYSTEMS INC (0001280452) (Issuer)

    6/3/26 5:31:58 PM ET
    $MPWR
    Semiconductors
    Technology

    Director Pyott David E I sold $1,145,853 worth of shares (3,830 units at $299.18) as part of a pre-agreed trading plan and converted options into 3,830 shares (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    6/3/26 4:25:20 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Cravatt Benjamin

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    6/3/26 4:23:40 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    $BIIB
    $CDW
    $FER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rothschild & Co Redburn initiated coverage on The Trade Desk with a new price target

    Rothschild & Co Redburn initiated coverage of The Trade Desk with a rating of Sell and set a new price target of $11.00

    5/28/26 8:58:34 AM ET
    $TTD
    Computer Software: Programming Data Processing
    Technology

    Ferrovial SE downgraded by Citigroup with a new price target

    Citigroup downgraded Ferrovial SE from Buy to Neutral and set a new price target of $70.00

    5/27/26 8:39:35 AM ET
    $FER
    Military/Government/Technical
    Industrials

    CDW upgraded by Analyst with a new price target

    Analyst upgraded CDW from Neutral to Overweight and set a new price target of $130.00

    5/27/26 8:28:02 AM ET
    $CDW
    Retail: Computer Software & Peripheral Equipment
    Technology

    $ALNY
    $BIIB
    $CDW
    $FER
    Leadership Updates

    Live Leadership Updates

    View All

    The Trade Desk Announces Nate Olmstead as Chief Financial Officer

    Interim CFO Tahnil Davis to Resume Previous Role as Chief Accounting Officer The Trade Desk (NASDAQ:TTD), a leading global advertising technology company, today announced the appointment of Nate Olmstead as Chief Financial Officer, effective July 9, 2026, to drive sustained accelerated growth and scale for the company. Olmstead will report to Jeff Green, The Trade Desk's CEO and Co-Founder. "From our earliest days, The Trade Desk has focused on building for the long term — for our clients, our partners and the broader open internet," said Jeff Green. "Nate deeply understands that mission and brings the experience, rigor and leadership to help guide our next phase of growth. I look forwa

    6/1/26 4:30:00 PM ET
    $TTD
    Computer Software: Programming Data Processing
    Technology

    WD Appoints Manuvir Das to Board of Directors

    Veteran technology executive and AI infrastructure leader brings deep expertise in enterprise AI, data infrastructure and cloud computing Western Digital Corporation (NASDAQ:WDC), the storage foundation of the AI-driven data economy, today announced the appointment of Manuvir Das to its board of directors, effective May 26, 2026. Das previously held senior leadership roles at NVIDIA, Dell EMC, and Microsoft, and brings deep expertise in enterprise AI, data infrastructure, and cloud computing. He currently serves as an Operating Partner in the Digital Infrastructure group at Stonepeak Partners LP, a position he assumed in April 2025. "Manuvir is a highly respected technology leader with

    5/28/26 9:00:00 AM ET
    $WDC
    Electronic Components
    Technology

    lululemon Enters into Cooperation Agreement with Chip Wilson; Laura Gentile and Marc Maurer to Join Company's Board of Directors

    lululemon athletica inc. (NASDAQ:LULU) today announced that it has entered into a cooperation agreement with Dennis J. "Chip" Wilson, who owns approximately 8.7% of the company's outstanding common stock. In connection with the agreement, Laura Gentile, former Chief Marketing Officer of ESPN, and Marc Maurer, former Co-Chief Executive Officer of On, will join the company's Board of Directors following the company's 2026 Annual Meeting of Shareholders. As part of the Board's ongoing refreshment efforts, the company also agreed to appoint an additional director with product and brand expertise in apparel to the Board by October 1, 2026. "On behalf of the Board, we are pleased to reach this

    5/27/26 7:30:00 AM ET
    $LULU
    Apparel
    Consumer Discretionary

    $ALNY
    $BIIB
    $CDW
    $FER
    Financials

    Live finance-specific insights

    View All

    EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

    Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus standard of care, supporting reduced long-term steroid exposureReduced flare rates and immune marker improvements: In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observed, supporting the potential of dapirolizumab pegol to address the complex burden of SLE BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Bi

    6/4/26 1:00:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

    Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus standard of care versus placebo plus standard of careFindings showed results in favor of dapirolizumab pegol plus standard of care versus placebo plus standard of care across endpoints, including multiple disease activity measures, severe flares, patient-reported outcomes, including fatigue, and glucocorticoid taperingResults support the continued development of dapirolizumab pegol; the ongoing confirmatory Phase 3 PHOENYCS FLY clinical trial is currently recruiting BRUSSELS, Belgium and CAMBRIDGE, M

    6/1/26 1:30:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    lululemon athletica inc. Announces First Quarter Fiscal 2026 Earnings Conference Call

    lululemon athletica inc. (NASDAQ:LULU) today announced that its financial results for the first quarter fiscal 2026 will be released Thursday, June 4, 2026. The company will host a conference call at 4:30 p.m. Eastern time to discuss the financial results. If you would like to participate in the call, please dial (833) 752-3550 or (647) 846-8290, if calling internationally, approximately 10 minutes prior to the start of the call. A live webcast of the conference call will be available online at: https://corporate.lululemon.com/investors/news-and-events/events-and-presentations. A replay will be made available online approximately 2 hours following the live call. About lululemon athlet

    5/21/26 6:30:00 AM ET
    $LULU
    Apparel
    Consumer Discretionary

    $ALNY
    $BIIB
    $CDW
    $FER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by The Trade Desk Inc.

    SC 13G/A - Trade Desk, Inc. (0001671933) (Subject)

    11/14/24 4:42:28 PM ET
    $TTD
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13G/A filed by Insmed Incorporated

    SC 13G/A - INSMED Inc (0001104506) (Subject)

    11/14/24 1:22:37 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Western Digital Corporation

    SC 13G/A - WESTERN DIGITAL CORP (0000106040) (Subject)

    11/14/24 1:22:34 PM ET
    $WDC
    Electronic Components
    Technology